197 related articles for article (PubMed ID: 36562888)
1. Assessment of the Performance of Non-invasive Criteria for the Evaluation of Clinically Significant Portal Hypertension in Patients with Compensated Advanced Chronic Liver Disease.
Jindal A; Agarwal S; Sharma S; Kumar M; Saraya A; Sarin SK
Dig Dis Sci; 2023 May; 68(5):2149-2157. PubMed ID: 36562888
[TBL] [Abstract][Full Text] [Related]
2. Noninvasive Diagnosis of Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease.
Pons M; Augustin S; Scheiner B; Guillaume M; Rosselli M; Rodrigues SG; Stefanescu H; Ma MM; Mandorfer M; Mergeay-Fabre M; Procopet B; Schwabl P; Ferlitsch A; Semmler G; Berzigotti A; Tsochatzis E; Bureau C; Reiberger T; Bosch J; Abraldes JG; Genescà J
Am J Gastroenterol; 2021 Apr; 116(4):723-732. PubMed ID: 33982942
[TBL] [Abstract][Full Text] [Related]
3. Prognostic performance of non-invasive tests for portal hypertension is comparable to that of hepatic venous pressure gradient.
Jachs M; Hartl L; Simbrunner B; Semmler G; Balcar L; Hofer BS; Schwarz M; Bauer D; Stättermayer AF; Pinter M; Trauner M; Reiberger T; Mandorfer M
J Hepatol; 2024 May; 80(5):744-752. PubMed ID: 38218352
[TBL] [Abstract][Full Text] [Related]
4. Non-invasive tests for clinically significant portal hypertension after HCV cure.
Semmler G; Lens S; Meyer EL; Baiges A; Alvardo-Tapias E; Llop E; Tellez L; Schwabl P; Mauro E; Escudé L; Díez C; Ibañez-Samaniego L; Puente Á; Fortea JI; Abadía M; Zanetto A; Conthe A; Hernandez-Évole H; Luzko Scheid IS; Jia J; Yoshiji H; Francque SM; Tsochatzis EA; Russo FP; Crespo G; Forns X; Bañares R; Villanueva C; Hernández-Gea V; Reiberger T; Bosch J; García Pagán JC; Mandorfer M;
J Hepatol; 2022 Dec; 77(6):1573-1585. PubMed ID: 36063968
[TBL] [Abstract][Full Text] [Related]
5. Validation of the New Diagnostic Criteria for Clinically Significant Portal Hypertension by Platelets and Elastography.
Podrug K; Trkulja V; Zelenika M; Bokun T; Madir A; Kanizaj TF; O'Beirne J; Grgurevic I
Dig Dis Sci; 2022 Jul; 67(7):3327-3332. PubMed ID: 34739624
[TBL] [Abstract][Full Text] [Related]
6. The usefulness of non-invasive liver stiffness measurements in predicting clinically significant portal hypertension in cirrhotic patients: Korean data.
Hong WK; Kim MY; Baik SK; Shin SY; Kim JM; Kang YS; Lim YL; Kim YJ; Cho YZ; Hwang HW; Lee JH; Chae MH; Kim HA; Kang HW; Kwon SO
Clin Mol Hepatol; 2013 Dec; 19(4):370-5. PubMed ID: 24459641
[TBL] [Abstract][Full Text] [Related]
7. The Sequential Application of Baveno VII Criteria and VITRO Score Improves Diagnosis of Clinically Significant Portal Hypertension.
Jachs M; Hartl L; Simbrunner B; Bauer D; Paternostro R; Scheiner B; Balcar L; Semmler G; Stättermayer AF; Pinter M; Quehenberger P; Trauner M; Reiberger T; Mandorfer M
Clin Gastroenterol Hepatol; 2023 Jul; 21(7):1854-1863.e10. PubMed ID: 36244661
[TBL] [Abstract][Full Text] [Related]
8. Validation of Baveno VII criteria for clinically significant portal hypertension by two-dimensional shear wave elastography.
He R; Liu C; Grgurevic I; Guo Y; Xu H; Liu J; Liu Y; Wang X; Shi H; Madir A; Podrug K; Zhu Y; Hua Y; Wang K; Wen J; Su M; Zhang Q; Li J; Qi X
Hepatol Int; 2024 Jun; 18(3):1020-1028. PubMed ID: 38740698
[TBL] [Abstract][Full Text] [Related]
9. Assessment of clinically significant portal hypertension by two-dimensional shear wave elastography.
Grgurevic I; Madir A; Trkulja V; Bozin T; Aralica G; Podrug K; Mikolaševic I; Tsochatzis E; O'Beirne J; Pinzani M
Eur J Clin Invest; 2022 Jun; 52(6):e13750. PubMed ID: 35040495
[TBL] [Abstract][Full Text] [Related]
10. Validation of Baveno VII criteria and other non-invasive diagnostic algorithms for clinically significant portal hypertension in hepatitis delta.
Jachs M; Sandmann L; Hartl L; Tergast T; Schwarz M; Bauer DJM; Balcar L; Ehrenbauer A; Hofer BS; Cornberg M; Lenzen H; Deterding K; Trauner M; Mandorfer M; Wedemeyer H; Reiberger T; Maasoumy B
J Hepatol; 2024 Mar; ():. PubMed ID: 38479612
[TBL] [Abstract][Full Text] [Related]
11. High accuracy of spleen stiffness measurement in diagnosing clinically significant portal hypertension in metabolic-associated fatty liver disease.
Odriozola A; Puente Á; Cuadrado A; Iruzubieta P; Arias-Loste MT; Redondo C; Rivas C; Fábrega E; Crespo J; Fortea JI
Liver Int; 2023 Jul; 43(7):1446-1457. PubMed ID: 36912787
[TBL] [Abstract][Full Text] [Related]
12. Assessment of portal hypertension severity using machine learning models in patients with compensated cirrhosis.
Reiniš J; Petrenko O; Simbrunner B; Hofer BS; Schepis F; Scoppettuolo M; Saltini D; Indulti F; Guasconi T; Albillos A; Téllez L; Villanueva C; Brujats A; Garcia-Pagan JC; Perez-Campuzano V; Hernández-Gea V; Rautou PE; Moga L; Vanwolleghem T; Kwanten WJ; Francque S; Trebicka J; Gu W; Ferstl PG; Gluud LL; Bendtsen F; Møller S; Kubicek S; Mandorfer M; Reiberger T
J Hepatol; 2023 Feb; 78(2):390-400. PubMed ID: 36152767
[TBL] [Abstract][Full Text] [Related]
13. Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis.
Lens S; Alvarado-Tapias E; Mariño Z; Londoño MC; LLop E; Martinez J; Fortea JI; Ibañez L; Ariza X; Baiges A; Gallego A; Bañares R; Puente A; Albillos A; Calleja JL; Torras X; Hernández-Gea V; Bosch J; Villanueva C; Forns X; García-Pagán JC
Gastroenterology; 2017 Nov; 153(5):1273-1283.e1. PubMed ID: 28734831
[TBL] [Abstract][Full Text] [Related]
14. Baveno VI and VII criteria are not suitable for screening for large varices or clinically significant portal hypertension in patients with hepatocellular carcinoma.
Allaire M; Campion B; Demory A; Larrey E; Wagner M; Rudler M; Roux C; Blaise L; Carrie NG; Thabut D
Aliment Pharmacol Ther; 2023 Aug; 58(3):346-356. PubMed ID: 37300315
[TBL] [Abstract][Full Text] [Related]
15. Noninvasive predictors of clinically significant portal hypertension in NASH cirrhosis: Validation of ANTICIPATE models and development of a lab-based model.
Rabiee A; Deng Y; Ciarleglio M; Chan JL; Pons M; Genesca J; Garcia-Tsao G
Hepatol Commun; 2022 Dec; 6(12):3324-3334. PubMed ID: 36214066
[TBL] [Abstract][Full Text] [Related]
16. Non-invasive detection of portal hypertension by enhanced liver fibrosis score in patients with different aetiologies of advanced chronic liver disease.
Simbrunner B; Marculescu R; Scheiner B; Schwabl P; Bucsics T; Stadlmann A; Bauer DJM; Paternostro R; Eigenbauer E; Pinter M; Stättermayer AF; Trauner M; Mandorfer M; Reiberger T
Liver Int; 2020 Jul; 40(7):1713-1724. PubMed ID: 32358998
[TBL] [Abstract][Full Text] [Related]
17. Non-invasive diagnosis and follow-up of portal hypertension.
Thabut D; Weil D; Bouzbib C; Rudler M; Cassinotto C; Castéra L; Serste T; Oberti F; Ganne-Carrié N; de Lédinghen V; Bourlière M; Bureau C
Clin Res Hepatol Gastroenterol; 2022 Oct; 46(8):101767. PubMed ID: 34332128
[TBL] [Abstract][Full Text] [Related]
18. ABC: a novel algorithm to stratify decompensation risk in patients with compensated advanced chronic liver disease (CHESS2108): an international, multicenter cohort study.
Liu C; Li J; Wong YJ; Xie Q; Hirooka M; Enomoto H; Kim TH; Hanafy AS; He R; Koizumi Y; Hiasa Y; Nishimura T; Iijima H; Jung YK; Yim HJ; Ma J; Zeng QL; Sarin SK; Qi X
Hepatol Int; 2022 Oct; 16(5):1105-1115. PubMed ID: 35606627
[TBL] [Abstract][Full Text] [Related]
19. Liver stiffness can predict decompensation and need for beta-blockers in compensated cirrhosis: a step beyond Baveno-VI criteria.
Jindal A; Sharma S; Agarwal S; Kumar M; Saraya A; Sarin SK
Hepatol Int; 2022 Feb; 16(1):89-98. PubMed ID: 35072932
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension.
Lens S; Baiges A; Alvarado-Tapias E; LLop E; Martinez J; Fortea JI; Ibáñez-Samaniego L; Mariño Z; Rodríguez-Tajes S; Gallego A; Bañares R; Puente Á; Albillos A; Calleja JL; Torras X; Hernández-Gea V; Bosch J; Villanueva C; García-Pagán JC; Forns X
J Hepatol; 2020 Dec; 73(6):1415-1424. PubMed ID: 32535060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
